Alzamend Neuro, Inc.
ALZN
$0.68
-$0.0206-2.94%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.42% | 15.70% | -34.83% | -59.77% | -70.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.00% | -53.20% | -72.70% | -74.28% | -50.96% |
| Operating Income | 61.00% | 53.20% | 72.70% | 74.28% | 50.96% |
| Income Before Tax | 60.96% | 53.15% | 72.38% | 74.24% | 50.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.96% | 53.15% | 72.38% | 74.24% | 50.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.96% | 53.15% | 72.38% | 74.24% | 50.93% |
| EBIT | 61.00% | 53.20% | 72.70% | 74.28% | 50.96% |
| EBITDA | 61.29% | 53.43% | 72.97% | 74.62% | 51.14% |
| EPS Basic | 95.01% | 90.95% | 76.70% | 75.85% | 54.40% |
| Normalized Basic EPS | 95.01% | 91.29% | 76.69% | 75.85% | 54.40% |
| EPS Diluted | 95.01% | 90.95% | 76.70% | 75.85% | 54.40% |
| Normalized Diluted EPS | 95.01% | 91.29% | 76.69% | 75.85% | 54.40% |
| Average Basic Shares Outstanding | 682.22% | 438.04% | 18.51% | 6.66% | 7.61% |
| Average Diluted Shares Outstanding | 682.22% | 438.04% | 18.51% | 6.66% | 7.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |